737 results about "Targeted drug delivery" patented technology

Described herein is a system for intravascular drug delivery system, which includes a reservoir implantable a blood vessel, an intravascular pump fluidly coupled to the reservoir and an anchor expandable into contact with a wall of the blood vessel to retain the system within the vasculature. Delivery conduits may be extend from the reservoir and are positionable at select locations within the vasculature for target drug delivery to select organs or tissues.

The invention relates to a hyaluronan and biodegradable high polymer modified material and a preparation method, in particular to a method for complex crosslinking and grafting of the hyaluronan and a derivative thereof with a biodegradable high polymer with active functional groups through a crosslinking agent. The method comprises the steps of taking the hyaluronan and the biodegradable high polymer as raw materials, conducting complex crosslinking or grafting reaction of a hyaluronan aqueous solution and at least one biodegradable high polymer solution with the presence of the crosslinking agent, and removing a solvent. According to the method, plural gel, an amphiphilic polymer, a graft polymer, a star polymer and a microsphere can be prepared. The method has the advantages that the reaction condition is simple, the utilization ratio of the crosslinking agent is high, the residual quantity of the crosslinking agent is small, and the gel is higher in thermostability and good in biological compatibility. The method is applicable to the fields of cosmetics, tissue filling and repair, biological stents, ophthalmonogy, sustained-release delivery and targeted drug delivery and the like, and has a wider application prospect.

Described herein is a system for intravascular drug delivery system, which includes a reservoir implantable a blood vessel, an intravascular pump fluidly coupled to the reservoir and an anchor expandable into contact with a wall of the blood vessel to retain the system within the vasculature. Delivery conduits may be extend from the reservoir and are positionable at select locations within the vasculature for target drug delivery to select organs or tissues.

A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles or microparticles (e.g., cross-linked gelatin) of the therapeutic agent (e.g., paclitaxel) also may be used. The nanoparticles or microparticles may be coated with a bioadhesive coating. Microspheres that agglomerate to block the entrance of the lymphatic ducts of the bladder to retard clearance of the microparticles through the lymphatic system also may be employed. This invention also uses drug-loaded gelatin and poly(lactide-co-glycolide) (PLGA) nanoparticles and microparticles to target drug delivery to tumors in the peritoneal cavity, bladder tissues, and kidneys.

Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and / or treating diseases and disease states caused by pathogenic cell populations.

The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and / or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

The present invention is directed to compositions and methods of using compositions comprising a scaffold with growth factors chemically immobilized thereto for inducing chondrogenesis and / or osteogenesis when implanted in vivo or osteogenesis or chondrogenesis in cultures in vitro. The compositions and methods enhance bone and cartilage growth. Also described are compositions and methods for targeted drug delivery.

A medical catheter comprising a proximal end having an opening for fluid containing a therapeutic drug, a distal end, the distal end defining at least one opening, and a porous portion covering the opening defined by the distal end. In one embodiment, the medical catheter comprises a proximal end having an opening for fluid containing a therapeutic drug, at least two distal ends, the proximal end connected to the two distal ends with a connector, the distal ends each defining at least one opening, a diffuser covering the opening of each distal end, and a separate restrictor downstream of the connector and upstream of each distal end to provide substantially equal flow through each distal end. An additional restrictor can also be placed upstream of the connector. In another embodiment, a combination diffuser and restrictor covers the opening of each distal end. In one embodiment, the diffuser can define tubes that extend from the inside surface of the diffuser to the outside surface of the diffuser, to permit more equal drug flow through the tubes defined therein.

A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.

The size and location of microsphere uptake / delivery are important determinants of the final biodistribution of oral microsphere systems. Formulations, kits, methods of administering the formulations, and using the kits are described herein. The formulations are oral dosage formulations. In one embodiment, the formulations contain microparticles and / or nanoparticles having a homogenous size range selected to optimize uptake in a specific region of the GI tract and target drug delivery to specific organs. In some embodiments, the dosage formulation contains an enteric coating and / or a magnetic material. In a preferred embodiment, the formulation contains a magnetic material and an active agent to be delivered, optionally the active agent is in the form of micro- or nano-particles. In some embodiments metallomucoadhesive materials and / or magnetic materials are employed as magnetic and / or mucoadhesive sources. Formulations containing magnetic materials can be localized using the kits and methods disclosed herein. In one embodiment, the method includes orally administering the formulation and applying an extracorporeal magnet to a site on the outside surface of the patient's body in an area that closely apposes the location in the gastrointestinal tract to which delivery of the formulation is desired. The extracorporeal magnet is applied for a suitable time period to allow for the drug to be released from the formulation and / or to allow for the formulation to adhere to the site. Both magnetic and mucoadhesive forces may be utilized to site-direct and retain the dosage form in the region of the gastrointestinal (GI) tract most suitable for the desired delivery.

The invention provide herein provides for a targeted drug delivery vehicle compositions, methods of manufacture, and methods of treatment for therapeutic applications.

The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hyperproliferative cell disease, particularly cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing an Eph family receptor tyrosine kinase, such as EphA2 or EphA4, for the treatment, management, or prevention of hyperproliferative diseases, particularly cancer. In one embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety attached to a delivery vehicle, and one or more therapeutic or prophylactic agents that treat or prevent a hyperproliferative disease, where the therapeutic or prophylactic agents are operatively associated with the delivery vehicle. In another embodiment, the method of the invention comprises administering to a subject a composition comprising a nucleic acid comprising a nucleotide sequence encoding an EphA2 or EphA4 targeting moiety and a therapeutic or prophylactic agent that treats or prevents a hyperproliferative disease. In yet another embodiment, the method of the invention comprises administering to a subject a composition comprising an EphA2 or EphA4 targeting moiety and a nucleic acid comprising a nucleotide sequence encoding an agent that treats or prevents a hyperproliferative disease, where the nucleic acid is operatively associated with the delivery vehicle. Pharmaceutical compositions are also provided by the present invention.

The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor-associated endothelial cells. In particular, the present invention provides a tumor-targeted drug delivery system comprising a NGR-containing molecule linked to a delivery vehicle encapsulating a therapeutic agent, preferably a drug, such as a cytotoxic agent or a chemotherapeutic agent. Specifically, the delivery systems of the present invention are capable of delivering an increased amount of therapeutic agent to a tumor as compared to other delivery systems. In particular, the delivery systems of the present invention are capable of accumulating a higher amount of therapeutic agent in a tumor, or in the vicinity of a tumor cell or tumor-supporting cell, resulting in exposure of the tumor cell and tumor-associated endothelial cell to therapeutic levels of the agent for a longer period of time as compared to other delivery systems. The present invention also describes pharmaceutical compositions comprising the delivery systems of the present invention. The present invention further relates to a tumor treatment comprising an increased amount of therapeutic agent delivered by the system of the present invention as compared to other delivery systems. The delivery systems and pharmaceutical compositions can be administered to a subject, preferably a human, alone or in combination, sequentially or simultaneously, with other prophylactic or therapeutic agents and / or anti-cancer treatments.

A targeted drug delivery device is provided. The device comprises an elongated member with proximal and distal ends, a plurality of infusion ports associated with the distal end of the elongated member, and a selector mechanism for selectively placing an introducer port into fluid communication with at least one infusion port. A method for treating tissue is also provided. The method comprises introducing a medical device into the tissue, selecting an region of the tissue to treat, positioning the medical device in proximity to the region, and introducing a medicament through the device to treat only that region.

The present invention provides a non-covalent coupling method for the preparation of sterically stabilized lipsomes which may be used for targeted drug delivery, e.g., pegylated liposomes. The method simplifies the attachment of targeting vectors to sterically stabilized liposomes. The present invention also provides a liposome composition comprising a compound of the formulaand a compound of the formula Z-Y, wherein Z is any compound capable of binding to a cellular receptor, and X and Y are compounds which can interact with each other non-convalently, and wherein the substituents n, F1 and F2 are as provided in the specification.

The invention belongs to the nanotechnical field, and discloses preparation of a methoxy polyethylene glycol-poly(lactic-co-glycolic acid)-polylysine(mPEG-PLGA-PLL) cationic polymer nano-drug delivery system and application thereof. The nano-drug delivery system can have multi-functional characteristics such as tumor targeting, reversing drug resistance and medical diagnosis functions through modification, and can be used for supporting organic medicaments, water-soluble medicaments, non-water-soluble medicaments, or developers for diagnosis. The preparation method is simple and convenient, is suitable for mass production, and is particularly suitable for the preparation of targeting drug delivery systems.

The invention discloses a tumor-targeted nanometer drug delivery system for cooperative chemotherapy and photodynamic therapy and a preparation method thereof. The drug delivery system is prepared from carboxymethyl chitosan, folate, a photosensitizer chlorine e6 and adriamycin, wherein the chlorine e6 and the folate are coupled to a carboxymethyl chitosan chain segment through an amido bond, and are loaded to polymer nanoparticles of the adriamycin through an ion exchange method. The nanometer material prepared by the method is high in yield, regular in shape and even in distribution. In-vivo and in-vitro experiments prove that the tumor targeting property of the nanometer preparation can be significantly improved by folate receptor mediation; enrichment on the tumor part is achieved and drug release is controlled. The photosensitizer is capable of effectively reversing the chemotherapy drug resistance and significantly inhibiting the growth of tumors after being irradiated by near-infrared light. Therefore, the related nanometer drug delivery system has good application prospect in the aspect of breast cancer treatment.

The invention is an apparatus and method for treatments and targeted drug delivery into a living patient, particularly but not exclusively using magnetic resonance (MR) imaging. The apparatus and method are useful in delivery to all types of living tissue and uses MR Imaging to track the location of drug delivery and estimating the rate of drug delivery. An MR-visible drug delivery device positioned at a target site (e.g., intracranial delivery) delivers a diagnostic or therapeutic drug solution into the tissue (e.g., the brain). The spinal distribution kinetics of the injected or infused drug agent are monitored quantitatively and non-invasively using water proton directional diffusion MR imaging to establish the efficacy of drug delivery at a targeted location.

The invention relates to a liver cell membrane bionic liposome drug carrier, a preparation method of the liver cell membrane bionic liposome drug carrier, and application of the liver cell membrane bionic liposome drug carrier. The liver cell membrane bionic liposome drug carrier is characterized in that (1) the liposome drug carrier has a cell membrane protein component; (2) the liposome drug carrier is capable of loading drug in vitro, and is used for cell targeting fusion release; (3) the cell membrane protein component of the liposome comes from immortalized human liver cells, and is used for conveying targeted shear plasmids of a hepatitis virus genome; (4) the cell membrane protein component of the liposome comes from an immortalized liver tumor cell line, and is used for targeted drug delivery of liver tumor. The liver cell membrane bionic liposome drug carrier can be used for in vivo targeted hepatic cell transmission and drug delivery of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) gene targeting plasmids.

Disclosed herein are novel targeted drug delivery and controlled release methods and compositions where optically absorbing nanoparticles, such as nanoshells, are functionalized on their surfaces with thermolabile molecules that bind the drug molecules to be delivered. The linkage between the thermolabile moiety on the nanoparticles and the drug is deliberately designed or selected to be temperature sensitive, so that upon illumination of the nanoparticle at a wavelength of light, the drug molecules on the nanoparticles will be released. Targeting molecules, such as antibodies, aptamers or other molecules like folic acid, can be concurrently bound to the nanoparticle surface to deliver the nanoparticle to specifically targeted cells or tissues prior to the photothermally induced drug release. In this way the nanoparticles can be advantageously concentrated on the target prior to illumination, which makes the disclosed compositions both a targeted delivery and a controllable drug release vehicle.

Magnetic nanoparticles are provided that have a superparamagnetic core and a nanoporous silica shell surrounding the core. The shell is functionalized with amine or S-nitrosothiol groups both inside and outside the nanopores. A process to provide such nanoparticles involves hydrolyzing tetraethoxysilane (TEOS) in a microemulsion of a superparamagnetic nanoparticle to form a superparamagnetic nanoparticle encapsulated by an incompletely hydrolyzed nanoporous silica shell, and hydrolyzing an amine-containing compound or a thiol-containing compound in situ in the presence of the incompletely hydrolyzed nanoporous silica shell before hydrolysis and densification of the silica shell is complete to functionalize the nanoporous silica shell with amine or thiol groups both inside and outside the nanopores and to maintain nanoporosity of the shell. Such magnetic nanoparticles are useful as carriers for chemical or biological species, particularly for magnetic resonance imaging, optical imaging, targeted drug delivery, cell delivery and magnetic separation applications.

Methods and systems for inducing and passively detecting stable cavitation and / or inertial cavitation for targeted drug delivery across a biological membrane are disclosed. Such methods include administering vesicles having a nucleating agent and a therapeutic drug to a vascular system of a patient, and providing an active interval of ultrasonic exposure substantially throughout a targeted treatment zone. The ultrasonic exposure is produced by a source transducer at a specified fundamental frequency, amplitude, duty cycle, and duration. The methods also include detecting a scattered ultrasonic wave, where the scattered ultrasonic wave is received by a detection transducer. Detection of the scattered ultrasonic wave is indicative of stable and / or inertial cavitation. The ultrasonic exposure is provided intermittently in the active intervals separated by rest periods, and substantially less ultrasonic exposure is provided during the rest period than during the active interval.

In one embodiment, balloons are intended for use in valvuloplasty of stenosed aortic valves, with a potential use for valvuloplasty of other heart valves as well. Their common special feature is that the entire or part of their external surface is covered by a drug that is eluted at the valve tissues during the balloon brief contact with them at the time of dilatation. The drug acts against the process of restenosis, which almost uniformly occurs after some time. The shape of the balloon can be the classical cylindrical or an hour-glass shape that facilitates targeted delivery of the drug at the valve tissues. Additional balloon shapes are described for usage after valvuloplasty is carried out in order to achieve targeted drug delivery in the upper or both surfaces of the leaflets, and for prolonged contact with the valve tissues without interruption of blood circulation. An advantage of the balloons is that the local delivery of the drug will significantly reduce the likelihood of restenosis. As a result the procedural benefits for the patient are sustained in the long term, and the procedure from alleviating progresses into end-therapy.

A variety of heparanase specific molecular probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific molecular probe for therapy of a condition associated with expression of heparanase; the use of a heparanase specific molecular probe for quantification of heparanase in a body fluid; the use of a heparanase specific molecular probe for targeted drug delivery; and the use of a heparanase specific molecular probe as a therapeutic agent.

The present invention provides bone-targeting polymeric drug delivery systems based on HPMA and related copolymers and methods of making thereof. The water-soluble bone-targeting polymeric conjugates of the present invention comprise water-soluble copolymer backbones (P) which are linked, via a first spacer (S1), with a bone-related therapeutic agents or drug (D) and, via a second spacer (S2), with a bone-targeting moiety (T).

A catheter described is a balloon angioplasty catheter either of Over the Wire design or the Rapid Exchange design and has an expansible sleeve over the balloon. The expansible sleeve is porous and is able to absorb large quantities of fluid and fluids containing anti-proliferative drugs or other bioactive agents. The porous sleeve also expands along with the balloon when the balloon is inflated making the porous sleeve in contact with the inner wall of the affected artery or body cavity. The pressure in the balloon can be increased or pulsed, using a piezoelectric transducer, to enhance the flow of the drug from the porous membrane into the vessel wall. The porous membrane can be left in contact for an extended time periods as the catheter contains an extra lumen to provide blood perfusion distal to the balloon. For those lesions necessitating extended drug delivery an additional lumen is provided to supply additional medicines to the lesions. As the drug(s) are passed into the tissue in way of squeezing the porous membrane, needles and the concept of diffusion are not used to deliver the drug and blood flow is not interrupted during drug delivery.

The invention relates to a mesoporous nano silicon ball compound targeting drug delivery system as well as a preparation method and application thereof. The preparation method of the mesoporous nano silicon ball compound targeting drug delivery system comprises the following steps: 1) preparing amino-functionalized drug loading mesoporous silicon dioxide microspheres; 2) preparing hyaluronic acid-hydrosulphonyl polypeptide-adriamycin (HA-RGD-DOX); 3) preparing mesoporous microsphere-hyaluronic acid-hydrosulphonyl polypeptide-adriamycin--paclitaxel (MSNs-HA-RGD-DOX_PTX); and 4) preparing fluorescent marker modified mesoporous microsphere-hyaluronic acid-hydrosulphonyl polypeptide-adriamycin--paclitaxel compound (MSNs-HA-RGD-DOX-PTX). The mesoporous nano silicon ball compound targeting drug delivery system has the beneficial effects that firstly multi-targeting synergistic drug delivery is realized, multiple tumour cells and tissues can be killed, and reversal drug resistance is good; secondly, blood stability is excellent; thirdly, invisibility, drug release degree and controlled release properties are good; fourthly, in vivo tracing function is good; and fifthly, the mesoporous nano silicon ball compound targeting drug delivery system has good general applicability.

The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and places the targeting agent on the exterior surface of a biodegradable nanoshell, wherein an active agent is loaded with the nanoshell.

The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and / or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

The invention relates to the biotechnical field, and concretely relates to a tumor cell targeting penetrating peptide, a polynucleotide molecule and a use thereof, and a targeting drug delivery system containing the tumor cell targeting penetrating peptide. The tumor cell targeting penetrating peptide is characterized in that the tumor cell targeting penetrating peptide contains a CPPs structure domain having cell penetrating peptide activity and an EFG third ring sample mimic peptide structure domain with specific targeting affinity to tumor cells. The tumor cell targeting penetrating peptide has a substantial cell penetrating effect, has the novel characteristics of cell specificity and species specificity, and can be used to diagnose tumor diseases and develop medicines required in the treatment process.